Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2002-12-30
2008-10-07
Foley, Shanon (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S388210
Reexamination Certificate
active
07432346
ABSTRACT:
A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.
REFERENCES:
patent: 5912143 (1999-06-01), Bandman et al.
patent: 6166194 (2000-12-01), Wong et al.
patent: WO-96/18730 (1996-06-01), None
patent: WO-98/40403 (1998-09-01), None
patent: WO0018925 (2000-04-01), None
patent: WO0061779 (2000-10-01), None
patent: WO0153836 (2001-07-01), None
Bellone et al. (Immunology Today, v20 (10), 1999, pp. 457-462.
Gaiger et al. (Blood, vol. 96, No. 4, Aug. 2000, pp. 1480-1489).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Slamon et al. (Science vol. 235, Jan. 1987, pp. 177-182).
Genes VI, Benjamin Lewin, 1997, excerpt from Chapter 29.
Greenbaum et al. (Genome Biology, 2003, vol. 4, Issue 9, pp. 117.1-117.8).
Greenbaum et al. Genome Biology, 2003, vol. 4, Issue 9, pp. 1 17. 1-1 17.8.
Bellone et al. Immunology Today, v 20 (10), 1999, pp. 457-462.
Gaiger c/ al. Blood, vol. 96, No. 4, Aug. 2000, pp. 1480-1489.
Shmon et al. Science vol. 235, Jan. 1987, pp. 177-182.
Tockman et al., Cancer Res, 1992, vol. 52, 2711s-2718s.
Genes VI (1997) by Benjamin Lewin (p. 847-848).
EMBL Database, Accession No. AA145922 (1996).
EMBL Database, Accession No. BX161415 (2003).
Israeli Office Action for Application No. 142194, dated mailed on Jul. 16, 2007, 2 pages (Translation Only).
Reiger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular, 4thed., Springer-Verlay, Berlin, (1976).
Alberts et al., Molecular Biology of Cell, 3rded., (1994) p. 465.
Ellis et al., U.S. Patent No. 5,922,546, Aug. 25, 1997, Issued U.S. Patent Sequences Database, Results 1.
Shantz and Pegg, Int. J. of Biochem and Cell Biol, (1999) 31:107-122.
McClean and Hill, Eur. J. of Cancer (1993) 29A:2432-2248.
Fu et al., EMBO Journal (1996) 15:4392-4401.
Marra et al., “The WashU-HHMI Mouse EST Project,” EMBL Database Acc. No. AA145922, Dec. 14, 1996, XP002132118, Abstract.
Strausberg et al., “National Cancer Institute, Cancer Genome Anatomy Project (OGAP),” EMBL Database Acc. No. A/808141, Jul. 8, 1999, XP 002132119, Abstract.
Strausberg, Aug. 30, 1999, dbEDT Id 2960907, GenBank Acc. Al872360.
International Search Report from PCT Application No. PCT/US99/23005.
U.S. Appl. No. 09/410,132, filed by Afar et al., on Sep. 30, 1999.
Preliminary Amendment from U.S. Appl. No. 09/410,132, filed Jan. 26, 2000.
Non-Final Office Action from U.S. Appl. No. 09/410,132, mailed on Nov. 21, 2000.
Amendment Under 37 C.F.R. § 1.111 from U.S. Appl. No. 09/410,132, filed Apr. 23, 2001.
Final Office Action from U.S. Appl. No. 09/410,132, mailed on Jul. 17, 2001.
Amendment Under 37 C.F.R. § 1.116 from U.S. Appl. No. 09/410,132, filed Nov. 19, 2001.
Advisory Action from U.S. Appl. No. 09/410,132, mailed on Jan. 29, 2002.
Declaration of Pia M. Chllita-Eid from U.S. Appl. No. 09/410,132, filed Jul. 17, 2002.
Notice of Allowance from U.S. Appl. No. 09/410,132, mailed on Aug. 27, 2002.
Examiner's First Report on Australian Patent Application No. 62855/99, dated Jun. 21, 2002.
Request to Amend a Complete Specification for Australian Patent Application No. 62855/99, dated Jun. 18, 2003.
Office Action from Canadian Patent Application No. 2,344,620, dated Jul. 31, 2007.
Office Action From EP Patent Application No. 99 950 130.7 - 2405, dated Jun. 8, 2005.
Response to Office Action from EP Patent Application No. 99 950 130.7 -2405, dated Oct. 13, 2005.
Office Action from EP Patent Application No. 99 950 130.7 - 2405, dated Jan. 8, 2007.
Response to Office Action from EP Patent Application No. 99 950 130.7 - 2405, dated May 18, 2007.
Office Action from EP Patent Application No. 99 950 130.7 - 2405, dated Jun. 8, 2007.
Notification of Defects in Israeli Patent Application No. 142194, dated Apr. 15, 2007.
Submissions for Israeli Patent Application No. 142194, dated Jul. 16, 2007.
Notifications of Defects in Israeli Patent Application No. 142194, dated Jul. 16, 2007.
Examiner's First Report on Australian Patent Application No. 2003259622, dated Jul. 14, 2005.
Request to Amend a Complete Specification fro Australian Patent Application No. 2003259622, dated Sep. 21, 2005.
Examiner's Report No. 2 on Australian Patent Application No. 2003259622, dated Oct. 7, 2005.
Request to Amend a Complete Specification fro Australian Patent Application No. 2003259622, dated Jun. 7, 2006.
Afar Daniel E.
Hubert Rene S.
Mitchell Stephen Chappell
Agensys, Inc.
Foley Shanon
Morrison & Foerster / LLP
Yao Lei
LandOfFree
Gene expressed in prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene expressed in prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene expressed in prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3988790